Baseline magnetic resonance imaging parameters and stroke outcome in patients treated by intravenous tissue plasminogen activator

被引:80
|
作者
Nighoghossian, N
Hermier, M
Adeleine, P
Derex, L
Dugor, JF
Philippeau, F
Ylmaz, H
Honnorat, J
Dardel, P
Berthezéne, Y
Froment, JC
Trouillas, P
机构
[1] Hop Neurol & Neurochirurg P Wertheimer, Biostat Unit, F-69003 Lyon, France
[2] CNRS, Cerebrovasc Dis Ctr, F-75700 Paris, France
[3] CNRS, Dept Radiol, F-75700 Paris, France
[4] CNRS, Creatis UMR 5515, F-75700 Paris, France
关键词
magnetic resonance imaging; diffusion-weighted magnetic resonance imaging; perfusion-weighted; stroke outcome; tissue plasminogen activator;
D O I
10.1161/01.STR.0000053850.64877.AF
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-We designed a prospective sequential pretreatment and posttreatment MRI study to assess the relation between neuroimaging parameters and clinical outcome in patients treated with intravenous recombinant tissue-type plasminogen activator (rtPA). Methods-Patients with symptoms of acute hemispheric ischemic stroke were recruited. The National Institutes of Health Stroke Scale (NIHSS) score was assessed at baseline and at days 1, 7, and 60, and the modified Rankin scale (mRS) at day 60, by which outcome was classified in terms of independence (mRS score 0, 1, or 2) or severe disability or death (mRS score 3 through 6), was assigned. Multimodal stroke MRI was performed at presentation and repeated at day 1. MRI procedures included magnetic resonance angiography, T2* gradient-echo sequence, echoplanar imaging, and isotropic diffusion- (DWI) and perfusion-weighted (PWI) imaging. Patients were treated with intravenous rtPA after MRI completion. Results-Twenty-nine patients (16 men and 13 women; mean+/-SD age, 65+/-14 years) underwent MRI; the mean time from symptom onset to treatment was 255 62 minutes. Twenty-six patients had a vessel occlusion, and 15 patients experienced a partial (Thrombolysis in Myocardial Infarction [TIMI]-2) or total (TIMI-3) recanalization at day 1, whereas 11 patients had a persistent occlusion. Mean NIHSS scores at day 60 were 5.7+/-5.4 if recanalization had occurred and 14+/-2 in cases of persistent occlusion. According to the mRS, 13 patients were independent (mRS 0 through 2), whereas severe disability or death (mRS 3 through 6) was observed in 15 patients. A better outcome was observed when recanalization was achieved (r= -0.68, P=0.0002). PWI volume and time to peak (TTP) within the DWI lesion assessed before therapy were correlated with day-60 NIHSS score (PWI volume: r=0.51, P=0.006, TTP: r=0.35, P=0.07). The day-0 DWI abnormality volume was well correlated with day-60 NIHSS score (r=0.58, P=0.001). Multiple regression linear analysis showed that 2 factors mainly influenced clinical outcome: (1) recanalization, with a high correlation with NIHSS score at day 60 (P=0.0001) and (2) day-0 DWI lesion volume, which is closely associated with day-60 NIHSS score (P=0.03). Conclusions-Baseline DWI volume and recanalization are the main factors influencing clinical outcome after rtPA for ischemic stroke.
引用
收藏
页码:458 / 463
页数:6
相关论文
共 50 条
  • [21] Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator-treated patients
    Alvarez-Sabín, J
    Molina, CA
    Montaner, J
    Arenillas, JF
    Huertas, R
    Ribo, M
    Codina, A
    Quintana, M
    STROKE, 2003, 34 (05) : 1235 - 1240
  • [22] Timing of recanalization and outcome in ischemic-stroke patients treated with recombinant tissue plasminogen activator
    Wei, Xiao-Er
    Zhao, Yu-Wu
    Lu, Jing
    Li, Ming-Hua
    Li, Wen-Bin
    Zhou, Ya-Jun
    Li, Yue-Hua
    ACTA RADIOLOGICA, 2015, 56 (09) : 1119 - 1126
  • [23] A Systemized Stroke Code Significantly Reduced Time Intervals for Using Intravenous Tissue Plasminogen Activator under Magnetic Resonance Imaging Screening
    Sohn, Sang-Wook
    Park, Hyun-Seok
    Cha, Jae-Kwan
    Nah, Hyun-Wook
    Kim, Dae-Hyun
    Kang, Myong-Jin
    Choi, Jae-Hyung
    Huh, Jae-Taeck
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2015, 24 (02): : 465 - 472
  • [24] Intravenous tissue plasminogen activator improves the outcome in very elderly Korean patients with acute ischemic stroke
    Hong, K.
    Lee, J.
    Choi, J.
    Cho, Y.
    Park, J.
    Park, T.
    Lee, K.
    Lee, J.
    Lee, S.
    Ko, Y.
    Cha, J.
    Kim, D.
    Kim, J.
    Lee, J. U. N.
    Kim, D.
    Yu, K.
    Oh, M.
    Lee, B.
    Kim, B.
    Bae, H.
    INTERNATIONAL JOURNAL OF STROKE, 2015, 10 : 137 - 138
  • [25] Intravenous Tissue Plasminogen Activator Improves the Outcome in Very Elderly Korean Patients with Acute Ischemic Stroke
    Choi, Jay Chol
    Lee, Ji Sung
    Park, Tai Hwan
    Park, Sang-Soon
    Cho, Yong-Jin
    Park, Jong-Moo
    Kang, Kyusik
    Lee, Kyung Bok
    Lee, Soo-Joo
    Ko, Youngchai
    Kim, Jae Guk
    Lee, Jun
    Cho, Ki-Hyun
    Kim, Joon-Tae
    Yu, Kyung-Ho
    Lee, Byung-Chul
    Oh, Mi-Sun
    Cha, Jae-Kwan
    Kim, Dae-Hyun
    Nah, Hyun-Wook
    Kim, Dong-Eog
    Ryu, Wi-Sun
    Kim, Beom Joon
    Bae, Hee-Joon
    Kim, Wook-Joo
    Shin, Dong-Ick
    Yeo, Min-Ju
    Sohn, Sung Il
    Hong, Jeong-Ho
    Lee, Juneyoung
    Hong, Keun-Sik
    JOURNAL OF STROKE, 2015, 17 (03) : 327 - 335
  • [26] Treatment outcome of intravenous tissue plasminogen activator in elderly patients.
    Mikamoto, M.
    Kamiyama, K.
    Endo, H.
    Osato, T.
    Kataoka, T.
    Watanabe, T.
    Fumoto, K.
    Noro, S.
    Murahashi, T.
    Honjo, K.
    Takahira, K.
    Nomura, R.
    Nakamura, H.
    Mikamoto, M.
    CEREBROVASCULAR DISEASES, 2014, 37 : 659 - 659
  • [27] Speed of thrombolysis and hemorrhage rates in patients with vertebrobasilar stroke treated with intravenous recombinant tissue plasminogen activator
    Iguchi, Y
    Chen, CI
    Shaltoni, HM
    Uchino, K
    Ribo, M
    Brunser, A
    Garami, Z
    Chernyshev, OY
    Choi, JY
    Alexandrov, AV
    STROKE, 2004, 35 (01) : 299 - 299
  • [28] Tissue Plasminogen Activator for Cortical Embolism Stroke with Magnetic Resonance Perfusion Imaging: A Report of Two Cases
    Yi, Kenichiro
    Inoue, Manabu
    Irie, Kenichi
    Mizoguchi, Tadataka
    Miwa, Kaori
    Toyoda, Kazunori
    Koga, Masatoshi
    CASE REPORTS IN NEUROLOGY, 2019, 11 (02) : 222 - 229
  • [29] Outcome differences among tissue plasminogen activator and non-tissue plasminogen activator patients in an active stroke center
    Sandhu, SK
    Benson, RT
    Libman, RB
    Bhatnagar, R
    ANNALS OF NEUROLOGY, 2002, 52 (03) : S26 - S26
  • [30] Time to Treatment With Intravenous Tissue Plasminogen Activator and Outcome From Acute Ischemic Stroke
    Saver, Jeffrey L.
    Fonarow, Gregg C.
    Smith, Eric E.
    Reeves, Mathew J.
    Grau-Sepulveda, Maria V.
    Pan, Wenqin
    Olson, DaiWai M.
    Hernandez, Adrian F.
    Peterson, Eric D.
    Schwamm, Lee H.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (23): : 2480 - 2488